FDA Approves Pediatric Risankizumab - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

  • By

  • Kathryn Wighton

  • June 29, 2026

  • 3 min

Share

Original Source(s)

FDA Approves Pediatric Risankizumab

  • by Kathryn Wighton

  • June 29, 2026

Related Content

The role of high-fiber diets in modulating the gut–lung axis and asthmatic inflammation

Impact of sensory training on healthcare provider care for neurodivergent children

Nafamostat mesilate for anticoagulation in pediatric trauma patients undergoing extracorporeal membrane oxygenation: a two-center observational study in Northwest China